NeuroMetrix has agreed to a joint venture with Cyberkinetics Neurotechnology Systems to develop a device for the treatment of peripheral nerve injuries. Under the deal, NeuroMetrix will invest $2 million for the development of the device for two years, with an opportunity to gain exclusive rights to the product once it reaches the market.

Related Summaries